Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)

Market Cap	1.76T
Revenue (ttm)	7.88B
Net Income (ttm)	-23.09B
Shares Out	30.11M
EPS (ttm)	-770.43
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	140,694
Average Volume	190,687
Open	58,100
Previous Close	57,700
Day's Range	55,900 - 58,600
52-Week Range	25,450 - 59,600
Beta	0.42
RSI	75.36
Earnings Date	Nov 11, 2025

About Mezzion Pharma

Mezzion Pharma Co.,Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company developing JURVIGO, which is in Phase 3 clinical trial for treatment option to improve the physiology and exercise capacity of Fontan patients 12 years and older. The company was formerly known as Dong-A Pharmtech Co., Ltd. and changed its name to Mezzion Pharma Co.,Ltd. in April 2013. Mezzion Pharma Co.,Ltd. was founded in 2002 and is headquartered in Seoul, South Korea.

• Industry: Pharmaceutical Preparations
• Founded: 2002
• Employees: 18
• Stock Exchange: KOSDAQ
• Ticker Symbol: 140410

Financial Performance

In 2024, Mezzion Pharma's revenue was 8.61 billion, a decrease of -72.85% compared to the previous year's 31.72 billion. Losses were -19.48 billion, 53.0% more than in 2023.